Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 6/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1702032 | 0.89 | TSHR (0.55) | TSHRMAPTPDE4AADORA2APDE4B | |
| SCHEMBL4771370 | 0.84 | ALDH1A1 (0.53) | TSHRSMN1; SMN2MAPTPDE4AADORA2A | |
| SCHEMBL14592881 | 0.80 | DAO (0.41) | TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL7832602 | 0.80 | ADRA1D (0.42) | TSHRSMN1; SMN2 | |
| SCHEMBL1546096 | 0.79 | MAPT (0.49) | TSHRSMN1; SMN2GLAMAPTPDE4A | |
| SCHEMBL3297433 | 0.79 | KMT2A (0.54) | TSHRSMN1; SMN2GLAMAPTPDE4A | |
| SCHEMBL10085010 | 0.79 | ADORA2B (0.42) | SMN1; SMN2GLAMAPTPDE4AADORA2A | |
| SCHEMBL8768828 | 0.78 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL4770759 | 0.78 | KMT2A (0.55) | TSHRSMN1; SMN2MAPTADORA3ADORA2B | |
| SCHEMBL9765877 | 0.77 | SMN1; SMN2 (0.42) | TSHRSMN1; SMN2GLAMAPTPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349848-B2 | Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors | Dogwoof Pharmaceuticals, Inc. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20090082347-A1 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC | 2009-03-26 | — | — | US | disclosed |
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7470697-B2 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors | ADENOSINE THERAPEUTICS, LLC (US) | 2008-12-30 | — | — | US | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080125425-A1 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2badenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2008-05-29 | — | — | US | disclosed |
| WO-2008027585-A2 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-06 | — | — | WO | disclosed |
| EP-1889845-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SmithKline Beecham P.L.C. (GB) | 2008-02-20 | — | — | EP | disclosed |
| EP-1678181-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005042534-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125425-A1 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2badenosine receptors | ADORA2B, ADORA2A, ADORA3 | TSHR 345/4885SMN1; SMN2 3877/4885GLA 4345/4885 |
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | TSHR 351/4885SMN1; SMN2 3995/4885GLA 3093/4885 |
| US-20090082347-A1 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADORA2B, ADORA2A, ADORA3 | TSHR 247/4885SMN1; SMN2 4068/4885GLA 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.